Researchers at the University of California, San Diego School of Medicine (UCSD) have identified a new way to regulate the uncontrolled growth of blood vessels, known as angiogenesis, an underlying mechanism in a broad range of diseases and conditions. David A. Cheresh, Ph.D., professor of pathology at the UCSD School of Medicine and associate director for translational research at the Moores UCSD Cancer Center, and colleagues at the cancer center and at the University of Michigan discovered how an “angiogenic switch” turns on and then developed a strategy to turn it back off. Their findings are published in the online edition of the journal Nature Medicine.

Researchers have long searched for the switching mechanism that converts normal healthy blood vessels from the resting state to the proliferative or diseased state. During normal blood vessel formation or regeneration, endothelial cells forming the inner layer of blood vessels are exposed to factors in the local microenvironment that initiate the switch, causing blood vessels to begin to expand.

Dr. Cheresh and colleagues identified a small microRNA (miR-132) responsible for controlling the switch. He described the process in terms of a car and its brakes: “In tumor vessels or in hemangiomas, this particular microRNA is abundant and capable of maintaining extensive vascular growth. The effect is similar to a car that’s speeding out of control because its gas pedal is stuck to the floor and its brakes aren’t working.”

The researchers designed a complementary microRNA, or anti-miR, that binds to and neutralizes the original microRNA. “This anti-miR therapy in effect restores functionality to the brake pedal and uncontrolled blood vessel growth comes to a halt,” said Cheresh, who noted the new anti-miR turned off the angiogenic switch controlling disease severity in mouse models of cancer and of disorders of the retina.

As part of their study, Cheresh and colleagues designed a nanoparticle that’s capable of delivering the microRNA or the anti-microRNA directly to the diseased or proliferating blood vessels. This delivery vehicle ensures the therapeutic benefit is maximized while reducing the possibility of toxicity or side effects.

By delivering more of this type of microRNA, the scientists said, it may be possible to promote new blood vessel development in patients who have suffered tissue damage from stroke, heart attacks, or diabetes. Conversely, treating patients with the anti-miR might reduce or inhibit blood vessel development in tumors or help reduce inflammation.
# # #